API | solanezumab

solanezumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Solanezumab is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
solanezumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Amyloid-beta A4 protein (Homo sapiens) ^UniProt
- Amyloid-beta A4 protein (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ly2062430 | ly 2062430 | ly-2062430 | solanezumab

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Alzheimer Disease (Phase 3)

Cognition Disorders (Phase 3)

Cognitive Dysfunction (Phase 1)

Dementia (Phase 2/Phase 3)

Healthy Volunteers (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue